Upstream Bio, Inc. (UPB) stock
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.08−0.02 (-0.95%)
Close on Nov 18, 2026Market cap $113.92MP/E –Yield –
Upstream Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Upstream Bio's operating income for the twelve months ending Sep 30, 2026 was -$175.53M. For fiscal 2025 it was -$160.36M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$160.36M | – |
| FY2024 | Dec 31, 2024 | -$77.76M | – |
| FY2023 | Dec 31, 2023 | -$40.11M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$43.38M | – |
| Q2 FY2026 | Jun 30, 2026 | -$42.37M | – |
| Q1 FY2026 | Mar 31, 2026 | -$43.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$46.17M | – |
| Q3 FY2025 | Sep 30, 2025 | -$37.83M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.35M | – |
| Q1 FY2025 | Mar 31, 2025 | -$32.01M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.39M | – |
See a number that looks wrong?